Valeant Pharmaceuticals International, Inc. (Stock Trading Symbol: VRX) has filed a letter from its Chairman and Chief Executive Officer, J. Michael (“Mike”) Pearson, with the U. S. Securities & Exchange Commission. Chairman Pearson, a lifetime management consultant before joining VRX, signs the letter as plain-old Mike. It is addressed to his “Colleague […]
In January 2014 the National Bureau of Economic Research, [“NBER”] the nation's leading nonprofit economic research organization, published a behavioral finance article titled “How Constraining Are Limits to Arbitrage? Evidence from a Recent Financial Innovation.” The study identifies a "recent class of short sellers" and found that Manuel P. […]
asensio.com provides access to Company specific data rooms.
asensio.com provides links in its reports to supporting documents to allow investors to review source materials and evaluate our representations. These documents are compiled in our data base and viewable and accessible by clicking on the description of each document from a sortable list. Access to the Data Rooms is provided under the “Report Record” main menu on our front page. Investor can go directly to our data rooms by clicking here
Asensio & Company, Inc. and Manuel P. Asensio are the only dedicated short sellers ever to have been members of FINRA. This unique-minority membership created complications in the regulatory relationship. Being the first activist short investors and among the first FINRA member firms with a website added to the complexity. A statement by Mr. Asensio is available here. Information necessary to obtain a meaningful understanding of the dispute is available in complete form HERE.
Click here to view asensio.com’s appearances on various television programs, including CNBC and Bloomberg TV. These appearances reflect asensio.com’s tradition of taking the time to engage in open meaningful dialogues including taking an active part in the public debate about investment valuation.
Asensio & Company, Inc.'s book published by John Wiley & Sons, Inc. titled "